Immix Biopharma Investor Presentation Deck
IMX-110 Opportunity: Soft Tissue Sarcoma - Remains An Unmet Medical Need
Select Approved Therapies & Clinical Trials in Soft Tissue
Sarcoma
mPFS
(months)
5
4
3
2
1
0
-20%
Judson
DOX 14
Chawla
DOX '15
Lorigan
DOX '07
0%
ران
gsk
Pazopanib
NOVARTIS
20%
MERCK
Pembrolizumab Bristol Myers Squibb
Nivolumab
+ Ipilimumab
40%
Eisai
Eribulin
Bristol Myers Squibb
Nivolumab
60%
80%
100%
STS Sub-Indication
Drugs Used To Treat Soft Tissue Sarcoma
Leiomyosarcoma
Liposarcoma
Undifferentiated
Pleomorphic Sarcoma
(Adapted From In et al, 2017)
Disease Control @ 2 mos
Median Progression
Free Survival
Dose Interruptions
due to Toxicity
Drug-Related SAEs
Overall Response Rate
% Of Patients With ≥ 3 Lines Of Treatment Prior to Therapy
Note: mPFS is Median Progression Free Survival Dollar amounts are annual drug sales. Adapted from: Lorigan et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or
metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007 Jul 20:25(21):3144-50. doi: 10.1200/3CO.2006.09.7717. Judson et al.
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-
2045(14)70063-4. Chawla et al. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015 Dec;1(9):1272-80. doi:
10.1001/jamaoncol 2015.3101. Tawbi et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-1501, doi:
10.1016/S1470-2045(17)30624-1. D'Angelo et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018
Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Schöffski et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Lancet 2016 Apr 16,387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. D'Angelo et al. Pilot study of NKTR214 and nivolumab in patients with sarcomas. Journal of Clinical Oncology 2019 37:15_suppl, 11010-11010. DOI:
10.1200/JC0.2019.37.15 suppl 11010. van der Graaf et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19,379(9829):1879-86. doi:
10.1016/S0140-6736(12)60651-5. Epub 2012 May 16.
1st Line
single-agent
doxorubicin (generic)
doxorubicin and
ifosfamide (generic)
liposomal doxorubicin
(generic, 1995 JJ)
68%
2.7 months
?
18%
0%
Doxorubicin
(Chawla et al, 2015)
2nd Line
Gemcitabine
docetaxel (generic)
Trabectedin
(2015)
Gemcitabine +
docetaxel (generic)
62%
4.2 months
57%
13%
●●●
S
10% (0% CR)
Trabectedin
(Demetri et al, 2015)
IMMIX
BIOPHARMA
3rd Line
Trabectedin
(2015)
Eribulin
(2010)
Pazopanib
(2009)
58%
2.6 months
33%
8%
4% (0% CR)
Eribulin
(Schöffski et al, 2016)
Note: CR is Complete Response. Adapted from: Chawla et al. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue
Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol.2015.3101. Demetri et al, Efficacy and Safety of
Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized
Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/3CO.2015.62.4734. Epub 2015 Sep 14. Schöffski et al. Eribulin versus
dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr
16:387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. In et al, Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical
considerations. Ther Adv Med Oncol. 2017 Aug;9(8):533-550. doi: 10.1177/1758834017712963. Epub 2017 Jun 15.
49View entire presentation